Sugi Predict

Sugi Predict / Compounds / SCHEMBL14900454

SCHEMBL14900454

SCHEMBL14900454

CB(O)N1C(=O)CC[C@H]1Cc1ccc(-c2cccc(Cl)c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM2 Q14416 1/20 0.45
▸ TAAR1 Q96RJ0 2/20 0.44
▸ MAOB P27338 2/20 0.39
▸ MMP2 P08253 1/20 0.38
▸ MMP9 P14780 1/20 0.38
▸ MMP8 P22894 1/20 0.38
▸ P2RX7 Q99572 1/20 0.38
▸ RORC P51449 1/20 0.38
▸ PGR P06401 3/20 0.37
▸ SLC6A7 Q99884 1/20 0.37
▸ TDP2 O95551 1/20 0.37
▸ HCRTR1 O43613 1/20 0.36
▸ HCRTR2 O43614 1/20 0.36
▸ MCHR1 Q99705 1/20 0.36
▸ CYP26A1 O43174 1/20 0.36
▸ MME P08473 1/20 0.36
▸ ACE P12821 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ MDM2 Q00987 1/20 0.36
▸ NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14900495 0.87 HCRTR1 (0.41) GRM2MMP2MMP9HCRTR1HCRTR2
SCHEMBL16939243 0.86 GRM2 (0.44) GRM2TAAR1HCRTR1HCRTR2MME
SCHEMBL14900568 0.83 RORC (0.39) MAOBP2RX7RORCMCHR1
SCHEMBL16939238 0.82 MME (0.36) MMEACE
SCHEMBL14900527 0.79 GRM2 (0.43) GRM2TAAR1MAOBMMP2MMP9
SCHEMBL14932460 0.77 GRM2 (0.41) GRM2TAAR1MMP2MMP9MMP8
SCHEMBL14900434 0.76 POLB (0.36) MDM2
SCHEMBL22639146 0.69 GRM2 (0.41) GRM2TAAR1MAOBMMP2MMP9
SCHEMBL14932461 0.69 KCNA5 (0.49) GRM2TAAR1MAOBPGRTDP2
SCHEMBL1908576 0.68 HCRTR1 (0.44) GRM2MMP2MMP9HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016835-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2024-06-25 — — US disclosed
US-20230285340-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP LLC (US) 2023-09-14 — — US disclosed
US-20180194718-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2018-07-12 — — US disclosed
US-9884807-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2018-02-06 — — US disclosed
US-20170368010-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-12-28 — — US disclosed
US-20170355664-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-12-14 — — US disclosed
US-9840460-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-12-12 — — US disclosed
US-20170327459-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-11-16 — — US disclosed
US-9688616-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-06-27 — — US disclosed
US-9682052-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-06-20 — — US disclosed
US-20160002148-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2016-01-07 — — US disclosed
US-20150376128-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-12-31 — — US disclosed
US-9150500-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-10-06 — — US disclosed
US-9108934-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-08-18 — — US disclosed
US-9096496-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-08-04 — — US disclosed
US-20150166469-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-06-18 — — US disclosed
US-8901169-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2014-12-02 — — US disclosed
US-20140343138-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2014-11-20 — — US disclosed
US-20140256702-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2014-09-11 — — US disclosed
US-20130109639-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC 2013-05-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285340-A1 NEPRILYSIN INHIBITORS MME, REN, ACE GRM2 3917/4885TAAR1 410/4885MAOB 47/4885
US-20160002148-A1 NEPRILYSIN INHIBITORS MME, REN, ACE GRM2 4073/4885TAAR1 595/4885MAOB 282/4885
US-20140256702-A1 NEPRILYSIN INHIBITORS MME, REN, ACE GRM2 3673/4885TAAR1 470/4885MAOB 304/4885
US-20130109639-A1 NEPRILYSIN INHIBITORS MME, REN, ACE GRM2 3917/4885TAAR1 410/4885MAOB 47/4885
US-20170368010-A1 NEPRILYSIN INHIBITORS MME, REN, ACE GRM2 3917/4885TAAR1 410/4885MAOB 47/4885
US-20150376128-A1 NEPRILYSIN INHIBITORS MME, REN, ACE GRM2 3673/4885TAAR1 470/4885MAOB 304/4885
US-20170355664-A1 NEPRILYSIN INHIBITORS MME, REN, ACE GRM2 4073/4885TAAR1 595/4885MAOB 282/4885
US-20150166469-A1 NEPRILYSIN INHIBITORS MME, REN, ACE GRM2 3673/4885TAAR1 470/4885MAOB 304/4885
US-20180194718-A1 NEPRILYSIN INHIBITORS MME, REN, ACE GRM2 3673/4885TAAR1 470/4885MAOB 304/4885
US-20140343138-A1 NEPRILYSIN INHIBITORS MME, REN, ACE GRM2 3917/4885TAAR1 410/4885MAOB 47/4885
US-20170327459-A1 NEPRILYSIN INHIBITORS MME, REN, ACE GRM2 3673/4885TAAR1 470/4885MAOB 304/4885
US-12016835-B2 Neprilysin inhibitors MME, REN, ACE GRM2 3917/4885TAAR1 410/4885MAOB 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback